Jefferies Raises Revenue, EPS Estimates for Agilent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Jefferies today raised its EPS estimate for Agilent Technologies to $2.63 from $2.60, on the strength of recent organic order trends and anticipated minimal effects from the Japanese earthquake and tsunami.

The investment firm also increased the share-price target to $56 from $55 and revenue estimates for full-year 2011 to $6.39 billion from $6.35 billion. It has a "Buy" rating on Agilent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.